Slide 1: Presentation to Investors
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: mmora@miscorp.com.au Website: www.biotron.com.au 15 October 2025 The Manager Companies ASX Limited 20 Bridge Street SYDNEY NSW 2000 (15 page by email) Dear Madam PRESENTATION TO INVESTORS I attach a PowerPo
Slide 2: Investor Webinar
INVESTOR WEBINAR ASX:BIT 15 October 2025
Slide 3: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These statements are statements t
Slide 4: Industry-leading experts focused on transformative viral treatments
Industry-leading experts focused on transformative viral treatments Experienced Board & Management team with pharma, finance and VC backgrounds Clinical stage company with portfolio of small molecule drugs targeting viral diseases with major health problems and large international markets Core disco
Slide 5: BIT225 – First in class broad spectrum antiviral drug
BIT225 – First in class broad spectrum antiviral drug A Promising BIT225 is unique andFirst-In-Class the first drugOral Treatment of its kind beingofboth HIV-1, HCVacting a direct and Other Viruses antiviral drug and an innate immune enhancer, which unlike other HIV drugs, has the potential to inhib
Slide 6: Acquisition of Sedarex Limited
Acquisition of Sedarex Limited - Sedarex Limited is a public unlisted Australian company holding global patents for SedRxTM, a safer, next- generation general anaesthetic - SedRx is a late-stage clinical asset - Broadens Biotron’s pipeline beyond antivirals - Dual-market potential - General anaesthe
Slide 7: Acquisition of Sedarex Limited
Acquisition of Sedarex Limited - Summary of acquisition terms: - Biotron to purchase 100% of Sedarex issued shares for: - 500 million BIT fully paid ordinary shares ($1.5M @ $0.003 per share) - $250,000 BIT shares subject to receipt of regulatory guidance pathway from EMA - $250,000 BIT shares subje
Slide 8: Financing lead by Peak Asset Management
Financing lead by Peak Asset Management - Commitments received for a $1M Placement (2 tranche) - Issue price of $0.003 per share, with one attaching option ($0.02 expiring 2 years from date of issue) for every 2 shares issued - Tranche 1 (under Listing Rule 7.1) – 199,086,876 shares ($597,260) - Tra
Slide 9: Introduction to SedRx
Introduction to SedRx Graeme Wald Director, Sedarex
Slide 10: Problem: Current anaesthetics may cause harm such as:
Problem: Current anaesthetics may cause harm such as: Reduce blood pressure • 43% of heart attacks during surgery are associated with low blood pressure • 6.8 day increase in hospital stay • Increases risk of stroke and kidney failure Reduce respiration & airway control • Leading cause of malpractic
Slide 11: Opportunity - Commercialising SedRx
Opportunity - Commercialising SedRx A reformulated*, safer general anaesthetic Indications Clinical Profile General anaesthesia (induction and Efficacy: comparable to propofol maintenance) A neuroactive anaesthetic Sedation for short Safety: superior to propofol (Improved formulation term procedures
Slide 12: Growing market for general anaesthetic drugs
Growing market for general anaesthetic drugs Other Propofol, Sevoflurane and Desflurane are 64% of the Midazolam 3% market and growing at ~4% per annum. 6% Dexmedetomidine Propofol Demand is driven by: 17% 27% $3.2B Aging population Revenue opportunity from Remifentanil a $4.7B total Knee, hip , car
Slide 13: SedRx - Low hurdles to commercialisation
SedRx - Low hurdles to commercialisation Successfully Potential for completed pre- FDA backing for a European clinical trial, Phase 505(b)(2) Medicines I trial, and a pilot pathway Agency abridged Phase III (IIa) trial approval • SedRx is better than the current leading general anaesthetics propofol
Slide 14: Summary
Summary - SedRx opens up significant development and commercial opportunities for Biotron - SedRx is a well differentiated product with significant advantages over current standard general anaesthetics, especially in aging population at risk of post-operative cognitive decline - Additional indicatio
Slide 15: Biotron Limited (ASX:BIT)
BIOTRON LIMITED (ASX:BIT) Michelle Miller Managing Director mmiller@biotron.com.au www.biotron.com.au +61 412313329